[144] Avidity Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Avidity Biosciences (RNA) Form 144 notice: The filing reports a proposed sale of 9,709 common shares on 08/13/2025 through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $448,847.07. The securities were recorded as acquired on 08/13/2025 by exercise of stock options and paid in cash. The filing also discloses prior 10b5-1 sales by the same person on 08/06/2025 of 81,434 shares for $3,480,272.61. The filer represents they do not know any material nonpublic information.

Insights

Securities Analyst

TL;DR: Small insider sale disclosed; size is immaterial relative to total outstanding shares.

The Form 144 shows a proposed sale of 9,709 shares valued at $448,847.07. With 128,653,337 shares outstanding reported in the filing, the planned sale amounts to roughly 0.0076% of the outstanding shares, while the prior 10b5-1 sale of 81,434 shares represented about 0.0633%. These percentages suggest the transactions are small in scale and unlikely to be material to market valuation, but they are relevant for disclosure and compliance monitoring.

Corporate Governance Expert

TL;DR: Disclosure follows Rule 144 and cites a 10b5-1 plan; filings indicate procedural compliance, not governance concerns.

The notice identifies the sale under Rule 144 and records an acquisition by option exercise and prior 10b5-1 plan sales, and includes the standard representation that the filer is not aware of material nonpublic information. These items are consistent with routine insider liquidity activity and documented trading plans. From a governance perspective, the filing raises no evident compliance red flags based on the information provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9709	448847.07	128653337	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/13/2025	Exercise of Stock Options	Issuer			9709	08/13/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for STEVEN GEORGE HUGHES 10578 Science Center Drive, Suite 125 San Diego CA 92121	Common	08/06/2025	81434	3480272.61

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Who is listed as the seller in the Form 144 for Avidity Biosciences (RNA)?

The filing references 10b5-1 Sales for STEVEN GEORGE HUGHES as the seller.

How many Avidity (RNA) shares are proposed for sale and what is the aggregate value?

The notice reports 9,709 shares to be sold with an aggregate market value of $448,847.07.

When and where is the sale scheduled to occur?

The proposed sale date is 08/13/2025 on NASDAQ through Morgan Stanley Smith Barney LLC.

How were the shares being sold acquired?

The shares were acquired on 08/13/2025 by exercise of stock options and payment was made in cash.

Were there recent prior sales by the same person?

Yes, the filing discloses a 10b5-1 sale on 08/06/2025 of 81,434 shares for $3,480,272.61.

Does the filer state they possess any material nonpublic information?

The filer represents by signing the notice that they do not know any material adverse information